Linked Accounts
About Company
Elucid is a Boston-based medical technology company specializing in AI-powered imaging analysis software for cardiovascular disease assessment. Their flagship product, PlaqueIQâ„¢, is the first and only non-invasive software validated against histopathology to quantify arterial plaque characteristics, including lipid-rich necrotic core, calcification, and intraplaque hemorrhage. This technology enables physicians to make more precise, personalized treatment decisions for patients with known or suspected cardiovascular disease .
Company Overview
-
Founded: 2013
-
Headquarters: 399 Boylston Street, Suite 400, Boston, MA 02116, USA
-
Alternate Address: 225 Main Street, Suite 15, Wenham, MA 01984, USA
-
Phone: +1-617-329-9487
-
Email: info@elucid.com
-
Website: elucid.com
Leadership Team
-
Kelly Huang, PhD – President & CEO
-
Blake Richards – Chief Operating Officer
-
Andrew Miller – Chief Technology Officer & SVP, Engineering
-
Windi Hary – Chief Regulatory & Quality Officer
-
Sophie Khem – SVP, Clinical Quality & Delivery
-
Amy Kruglak – SVP, People & Leadership Development
-
Kevin Mathews – SVP, Marketing
-
Amir Ahmadi, MD – Chief Scientific Advisor
Recent Developments
-
In November 2023, Elucid raised $80 million in a Series C funding round led by Elevage Medical Technologies to accelerate the commercialization of its AI-powered diagnostic tools .
-
The company received FDA 510(k) clearance for its PlaqueIQâ„¢ image analysis software in October 2024, marking it as the first software validated on ground-truth histology for plaque characterization .
-
Elucid has expanded its leadership team and moved into new headquarters in Boston to support its growth and the upcoming commercial launch of PlaqueIQâ„¢
Be a First Reviewer